X

Trial Profile

A Phase 1b Study of TAK-659 in Combination With Venetoclax for Adult Patients With Previously Treated Non-Hodgkin Lymphoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mivavotinib (Primary) ; Venetoclax (Primary)
Indications Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions
Sponsors Takeda Oncology

Most Recent Events

23 Aug 2021 Status changed from active, no longer recruiting to completed.
07 Apr 2021 Planned End Date changed from 14 Apr 2021 to 24 Aug 2021.
07 Apr 2021 Planned primary completion date changed from 17 Mar 2021 to 24 Aug 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com